Sample size re-estimation in adaptive enrichment design
نویسندگان
چکیده
منابع مشابه
Sample size re-estimation for adaptive sequential design in clinical trials.
There is considerable interest in methods that use accumulated data to modify trial sample size. However, sample size re-estimation in group sequential designs has been controversial. We describe a method for sample size re-estimation at the penultimate stage of a group sequential design that achieves specified power against an alternative hypothesis corresponding to the current point estimate ...
متن کاملSample size re-estimation in clinical trials.
Adaptive clinical trials are becoming very popular because of their flexibility in allowing mid-stream changes of sample size, endpoints, populations, etc. At the same time, they have been regarded with mistrust because they can produce bizarre results in very extreme settings. Understanding the advantages and disadvantages of these rapidly developing methods is a must. This paper reviews flexi...
متن کاملSample size estimation in epidemiologic studies
This review basically provided a conceptual framework for sample size calculation in epidemiologic studies with various designs and outcomes. The formula requirement of sample size was drawn based on statistical principles for both descriptive and comparative studies. The required sample size was estimated and presented graphically with different effect sizes and power of statistical test at 95...
متن کاملInterim sample size re-estimation in the IIVOP trial
The IIVOP trial is a cross-over trial which examines the effect of the drug ivabridine in reducing pain in an enriched healthy volunteer pain model. The trial was designed based on very limited information, and as such an interim analysis was built into the design to allow the re-estimation of the sample size requirements based on updated trial parameters. The blinded data will be used to asses...
متن کاملAdaptive two-stage bioequivalence trials with early stopping and sample size re-estimation
Bioequivalence between two products has to be demonstrated as an essential part of the generic approval process (new formulation vs. innovator product), bridging an innovator’s product from the formulation used in clinical phase III to the marketed formulation, or in case of major variations of an approved product. The most common design of bioequivalence studies is a twosequence two-period two...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Contemporary Clinical Trials
سال: 2021
ISSN: 1551-7144
DOI: 10.1016/j.cct.2020.106216